Adnexus Buy Aimed At Enhancing Bristol’s Transformation To Biopharma Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition valued at $430 million comes seven months after firms signed oncology development deal, which "exceeded our expectations," Bristol told "The Pink Sheet" DAILY.
You may also be interested in...
Anaphore Will Focus On Trimeric Proteins In Auto-Immune, Oncology Settings
Private biotech raises $25 million in Series A deal involving three venture capital funds.
Anaphore Will Focus On Trimeric Proteins In Auto-Immune, Oncology Settings
Private biotech raises $25 million in Series A deal involving three venture capital funds.
BMS Licenses Kai Heart Drug For $227 Million
Delta protein kinase C inhibitor was given up by Daiichi Sankyo in 2007.